Make your money go further for just 25p per day

AIM IHT

Novacyt: on these numbers, the cheapest stock on the market

Novacyt Versalab image

AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?


Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:


Revenue +2400% to €311.6m (£277.0m) including revenue in the second half of the year of €239.2m (£213.7m).
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Novacyt SA

Novacyt: shares take a beating

09/04/2021 · Company Insights

AIM’s top performer in 2020 has fallen back to earth after a disappointing trading update. Are…


Eclectic delights of AIM

24/03/2021 · Company Insights

Bonkers Bargains, new Covid tests, kettle controls, video game developers and franchised lettings – such are…


More Company Insights

AIM new arrivals April 2021

Upgrades and fund raises

30/04/2021 · CVS Group · Eleco plc

Stonking Small Caps: enjoying a rising tide of revenue

30/04/2021